Article Figures & Data
Figures
- FIG 1
PBMCs from the patient were used for the establishment of an LCL. Generation of autologous LMP-specific CTLs from PBMCs was achieved by stimulating the PBMCs three times (days 0, 7, and 14) with γ-irradiated peptide epitope-coated LCLs at a ratio of 30:1 and culturing them in RPMI 1640 containing 10% fetal bovine serum with 40 IU of interleukin 2 (IL-2). CTLs were tested for LMP specificity in a 51Cr release assay, using autologous PHA blast cells or LCLs as target cells. The PHA blast cells were coated with 10−5 M and 10−7 M peptide epitopes. Autologous LCLs and an HLA-mismatch LCL were used as controls. Responses to the HLA A11-restricted peptide SSCSSCPLSK (SSC) were detected. MM, mismatch.
- FIG 2
EBV DNA level variations in PBMCs and plasma before and after CTL adoptive therapy. Blood was taken before and various days after each infusion. The x axis indicates days after initial treatment. Arrows indicate days of infusion. The y axis indicates EBV copy numbers.
- FIG 3
Images of chest CT scan performed before (a) and 3 months after (b) adoptive immunotherapy.
